Adoptive cell-based immunotherapy is based on the introduction of activated (instructed) immune cells with a high microbicidal activity directly into the focus of a chronic infection. Recurrence of the disease may be an indication for a repeat procedure.

Adoptive cell-based immunotherapy can be useful for the treatment of the following diseases.

  • Chronic cystitis
  • Chronic sinusitis



  1. Venous blood in the volume of 150 ml is taken once from a patient.
  2. The immune cells obtained from the patient’s blood are activated (instructed) in vitro by the original method for 1-2 days.
  3. The activated cells are injected directly into the site of a chronic infection.
  4. Treatment is carried out on an outpatient basis. In the case of developing a relapse, a repeat procedure is possible.


Main benefits and advantages of adoptive cellular immunotherapy:

  • Long-lasting clinical effects due to activated immune cells.
  • Decreased drug load on the body.
  • The absence of significant side effects and absolute contraindications
  • The possibility and feasibility of re-treatment in the case of developing a recurrence of the disease.
  • Wide possibilities of combining with other methods of treatment, including physiotherapy.


Related scientific publications:

  • T-cell therapy for chronic viral hepatitis.
    Bertoletti A, Tan AT, Koh S. Cytotherapy. 2017 Aug 25. pii: S1465-3249(17)30656-4. doi: 10.1016/j.jcyt.2017.07.011. [Epub ahead of print] Review.
  • Adoptive T-cell therapy in the treatment of viral and opportunistic fungal infections.
    Mancini N, Marrone L, Clementi N, Sautto GA, Clementi M, Burioni R. Future Microbiol. 2015;10(4):665-82. doi: 10.2217/fmb.14.122. Review.
  • γδ T cells and their potential for immunotherapy.
    Wu YL, Ding YP, Tanaka Y, Shen LW, Wei CH, Minato N, Zhang W. Int J Biol Sci. 2014 Jan 10;10(2):119-35. doi: 10.7150/ijbs.7823. eCollection 2014. Review.
  • Dendritic cell-based vaccines in treating recurrent herpes labialis: Results of pilot clinical study.
    Leplina O, Starostina N, Zheltova O, Ostanin A, Shevela E, Chernykh E. Hum Vaccin Immunother. 2016 Dec;12(12):3029-3035. doi: 10.1080/21645515.2016.1214348. Epub 2016 Jul 26.
  • Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.
    Van Brussel I, Berneman ZN, Cools N. Mediators Inflamm. 2012;2012:690643. doi: 10.1155/2012/690643. Epub 2012 Jul 18. Review.